Form 4: GeneDx Director Sells Shares in Pre-Arranged Plan

GeneDx Holdings Corp. Director Jason Ryan sold 39,222 shares of Class A Common Stock on August 27, 2025, through a pre-arranged 10b5-1 plan.

Summary

• Jason Ryan, a Director of GeneDx Holdings Corp. (WGS), reported the sale of 39,222 shares of Class A Common Stock.
• The transactions occurred on August 27, 2025.
• Sales were executed at weighted average prices ranging from $125.0729 to $130.0103 per share.
• The sales were conducted under a Rule 10b5-1(c) pre-arranged trading plan.
• A significant portion of the shares (38,072) were sold indirectly through the Jason Ryan 2024 GRAT, where Ryan is the trustee and sole annuitant, retaining beneficial ownership.
• 1,150 shares were sold from direct ownership.
• Following these transactions, Ryan beneficially owns 115,188 shares (103,284 indirectly via GRAT and 11,904 directly).

Sentiment

Score: 4

Explanation: The sale of shares by a director, even under a pre-arranged 10b5-1 plan, can be viewed with slight caution as it reduces insider ownership. However, the existence of a 10b5-1 plan suggests the transaction was not based on immediate, non-public information, which mitigates the negative sentiment.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not based on immediate, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This insider transaction report is specific to an individual's stock dealings and does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The sales involved shares held indirectly by the Jason Ryan 2024 GRAT, where Jason Ryan is the trustee and sole annuitant, maintaining beneficial ownership. This is a common estate planning vehicle for insiders.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a signal, though the 10b5-1 plan suggests it is not based on new information. The reduction in direct insider ownership could be a minor concern for some investors.

Key Dates

Recommendation

While insider selling can sometimes signal a lack of confidence, the execution under a Rule 10b5-1 plan suggests these are pre-scheduled transactions, likely for personal financial planning or diversification, rather than a reaction to new negative company developments. Without additional information on company performance or strategic shifts, a 'hold' recommendation is appropriate, acknowledging the insider sale but not overreacting given the 10b5-1 context.

Keywords

GeneDx Holdings Corp, WGS, Insider Selling, Form 4, Jason Ryan, Director, Stock Sale, 10b5-1 Plan, Class A Common Stock, GRAT